Probable Alzheimer's Disease Patients Presenting as “Focal Temporal Lobe Dysfunction” Show a Slow Rate of Cognitive Decline

2011 ◽  
Vol 18 (1) ◽  
pp. 144-150 ◽  
Author(s):  
Camillo Marra ◽  
Giampiero Villa ◽  
Davide Quaranta ◽  
Alessandro Valenza ◽  
Maria Gabriella Vita ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Semantic Memory ◽  
Temporal Lobe ◽  
Memory Impairment ◽  
Anterograde Amnesia ◽  
Continuous Series ◽  
Cognitive Domains ◽  
Rate Of Progression

AbstractSeveral authors have recently shown that anterograde amnesia is often associated with semantic memory impairment in amnesic MCI patients. Similarly, after the MCI condition, some patients who convert to Alzheimer's disease (AD) show the classic onset (cAD) characterized by the impairment of memory and executive functions, whereas other AD patients show isolated defects of episodic and semantic memory without deficits in other cognitive domains. The latter have been considered an AD variant characterized by ‘focal Temporal Lobe Dysfunction’ (TLD). The aim of the present study was to assess the differences in disease progression between cAD and TLD. For this purpose a continuous series of newly diagnosed probable AD patients presenting as cAD (n = 30) and TLD (n = 25), matched for severity, and 65 healthy controls underwent a comprehensive neuropsychological evaluation at baseline; TLD and cAD were re-evaluated at a 24-month follow-up. At follow-up, TLD patients showed no significant worsening of cognitive functions, whereas cAD subjects displayed a significant worsening in all explored cognitive domains. In conclusion, our results confirm that probable AD presenting as TLD represents a specific onset of AD characterized by a slower rate of progression. (JINS, 2012, 18, 144–150)

The Semantic Memory Impairment of Alzheimer's Disease: Category-Specific?

Cortex ◽  
1996 ◽  
Vol 32 (1) ◽  
pp. 143-153 ◽  
Author(s):  
Lynette J. Tippett ◽  
Murray Grossman ◽  
Martha J. Farah
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Semantic Memory ◽  
Memory Impairment ◽  
Disease Category

P4-093: Semantic memory impairment in Alzheimer's disease and frontotemporal dementia is associated with semantic network degradation

2011 ◽  
Vol 7 ◽  
pp. S734-S734
Author(s):  
Kimiko Domoto-Reilly ◽  
Daisy Sapolsky ◽  
Michael Brickhouse ◽  
Mark Hollenbeck ◽  
Brad Dickerson
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Frontotemporal Dementia ◽  
Semantic Memory ◽  
Memory Impairment ◽  
Semantic Network

Neuroanatomical correlates of semantic memory impairment seen in normal aging and early Alzheimer's disease, as measured by functional MRI

NeuroImage ◽  
2001 ◽  
Vol 13 (6) ◽  
pp. 650
Author(s):  
Richard J. Clarke ◽  
Audra J. Parker ◽  
Elizabeth A. Kensinger ◽  
John H. Growdon ◽  
Suzanne Corkin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Functional Mri ◽  
Semantic Memory ◽  
Memory Impairment ◽  
Normal Aging ◽  
Early Alzheimer’S Disease

Semantic Memory Impairment in Alzheimer's Disease

1996 ◽  
Vol 18 (5) ◽  
pp. 648-665 ◽  
Author(s):  
Irene Daum ◽  
Gerlinde Riesch ◽  
Giuseppe Sartori ◽  
Niels Birbaumer
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Semantic Memory ◽  
Memory Impairment

scholarly journals A 12-month Randomised Pilot Trial of the Alzheimer’s and Music Therapy Study: A Feasibility Assessment of Music Therapy and Physical Activity in Patients with Mild-to-Moderate Alzheimer’s Disease

2022 ◽  
Author(s):  
Anna Maria Matziorinis ◽  
Birthe Kristin Flo ◽  
Stavros Skouras ◽  
Kathrine Dahle ◽  
Tobba Therkildsen Sudmann ◽  
...  
Keyword(s):  
Physical Activity ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Experimental Design ◽  
Music Therapy ◽  
Memory Impairment ◽  
Neuropsychological Test ◽  
Pilot Trial ◽  
Neuropsychological Test Battery

Abstract Background: The Alzheimer’s and Music Therapy (ALMUTH) study is the first randomised controlled trial (RCT) design with 12 months of active non-pharmacological therapy (NPT) implementing music therapy (MT) and physical activity (PA) for participants with Alzheimer’s disease (AD). The aim of the present article is to retrospectively examine the inclusion of mild-to-moderate Alzheimer’s Disease patients into the main ALMUTH study protocol and to determine if continued inclusion of AD patients is warranted. Methods: The randomised pilot trial was conducted as a parallel three-arm RCT, reflecting the experimental design of the ALMUTH study. The trial was conducted in Bergen, Norway and randomisation (1:1:1) was performed by an external researcher. The study was open label and the experimental design features two active NPTs: MT and PA, and a passive control (no intervention, CON) in Norwegian speaking patients with AD who still live at home and could provide informed consent. Sessions were offered one time per week (up to 90 minutes) up to 40 sessions over the period of 12 months. Baseline and follow-up tests included a full neuropsychological test battery and three magnetic resonance imaging (MRI) measurements (structural, functional, and diffusion weighted imaging). Feasibility outcomes were assessed and were determined as feasible if they met the target criteria. Results: 18 participants with a diagnosis of mild-to-moderate AD were screened, randomised, and tested at baseline and after a 12-month follow-up interval. Participants were divided into three groups: MT (n=6), PA (n=6), and CON (n=6). Results of the study revealed that the ALMUTH protocol in patients with AD is not feasible. Adherence to protocol was poor (50% attended sessions), the presence of 50% attrition rates, 50% retention rates, insufficient and costly recruitment, issues with study fidelity, and many issues raised by staff. Recruitment status is still ongoing and the main study has been expanded to include milder forms of memory impairment. No adverse events were reported by the patients or their caregivers. Conclusions: The pilot trial was not deemed feasible in patients exclusively with AD. To mitigate this, the ALMUTH study has expanded the recruitment criteria to include participants with milder forms of memory impairment (pre-AD) in addition to expanding the neuropsychological test battery. The ALMUTH study is currently ongoing. Trial Registration: Norsk Forskningsråd (NFR) funded. Regional Committees for Medical and Health Research Ethics (REC-WEST: reference number 2018/206). ClinicalTrials.gov: NCT03444181 (registered retrospectively 23 February 2018, https://clinicaltrials.gov/ct2/show/NCT03444181).

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease

2009 ◽  
Vol 40 (1) ◽  
pp. 135-145 ◽  
Author(s):  
B. Schmand ◽  
H. M. Huizenga ◽  
W. A. van Gool
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Effect Size ◽  
Medial Temporal Lobe ◽  
Memory Impairment ◽  
Effect Sizes ◽  
Elderly Subjects ◽  
Csf Biomarkers ◽  
Preclinical Ad

BackgroundAbnormal levels of biomarkers in cerebrospinal fluid (CSF) and atrophy of medial temporal lobe (MTL) structures on magnetic resonance imaging (MRI) are being used increasingly to diagnose early Alzheimer's disease (AD). We evaluated the claim that these biomarkers can detect preclinical AD before behavioural (i.e. memory) symptoms arise.MethodWe included all relevant longitudinal studies of CSF and MRI biomarkers published between January 2003 and November 2008. Subjects were not demented at baseline but some declined to mild cognitive impairment (MCI) or to AD during follow-up. Measures of tau and beta-amyloid in CSF, MTL atrophy on MRI, and performance on delayed memory tasks were extracted from the papers or obtained from the investigators.ResultsTwenty-one MRI studies and 14 CSF studies were retrieved. The effect sizes of total tau (t-tau), phosphorylated tau (p-tau) and amyloid beta 42 (aβ42) ranged from 0.91 to 1.11. The effect size of MTL atrophy was 0.75. Memory performance had an effect size of 1.06. MTL atrophy and memory impairment tended to increase when assessed closer to the moment of diagnosis, whereas effect sizes of CSF biomarkers tended to increase when assessed longer before the diagnosis.ConclusionsMemory impairment is a more accurate predictor of early AD than atrophy of MTL on MRI, whereas CSF abnormalities and memory impairment are about equally predictive. Consequently, the CSF and MRI biomarkers are not very sensitive to preclinical AD. CSF markers remain promising, but studies with long follow-up periods in elderly subjects who are normal at baseline are needed to evaluate this promise.

Semantic Memory Impairment in the Earliest Phases of Alzheimer’s Disease

2005 ◽  
Vol 19 (2-3) ◽  
pp. 75-81 ◽  
Author(s):  
Asmus Vogel ◽  
Anders Gade ◽  
Jette Stokholm ◽  
Gunhild Waldemar
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Semantic Memory ◽  
Memory Impairment

scholarly journals Follow-Up of 53 Alzheimer Patients with the MODA (Milan Overall Dementia Assessment)

1997 ◽  
Vol 10 (4) ◽  
pp. 129-131
Author(s):  
E. Capitani ◽  
L. Manzoni ◽  
H. Spinnler
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Longitudinal Survey ◽  
Decline Rate ◽  
Rate Of Progression

Fifty-three patients affected by Alzheimer’s disease entered a longitudinal survey aimed at studying which factors influence the rate of progression, assessed by means of the Milan Overall Dementia Assessment (MODA). The second examination was carried out, on average, after 16 months from the first assessment. Only age proved to influence the decline rate, which was faster in elders.

Sign in / Sign up

Export Citation Format

Share Document